Collaboration to use companion diagnostics for cholangiocarcinoma treatment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/patpitchaya)
(Image: Getty/patpitchaya)

Related tags: Oncology, Developmental biology, In vitro, diagnostic

Incyte Corporation and Foundation Medical announced an agreement for the use of Foundation’s companion diagnostics tool in Incyte’s drug development.

The companies will focus on developing Foundation Medical’s companion diagnostics (CDx) platform to enable testing of Incyte’s proprietary treatment.

The initial CDx will include detection of activating fibroblast growth factor receptor (FGFR2) translocations. FGFR’s play a role in tumor cell survival and migration. Incyte stated that the activation of mutations, translocations and gene amplifications in FGFRs is closely related with the development and growth of cancers like cholangiocarcinoma.

The CDx will work as a tool in the development of pemigatinib, Incyte’s FGFR1/2/3 inhibitor​. The drug is in ongoing Phase II studies investigating the safety and efficacy of pemigatinib as a monotherapy through Incyte’s FIGHT clinical development program.

Foundation’s CDx, FoundationOneCDx, is an in vitro​ diagnostic device that is intended to be used as a companion device to determine the efficacy of the treatment of targeted therapies. The US Food and Drug Administration (FDA) approved device also will provide tumor mutation profiling.

Several CROs have chosen to have companion diagnostic labs, such as Pfizer​, Quintiles​, and Almac​.

Cholangiocarcinoma

Cholangiocarcinoma is a rare form of cancer that impacts the liver’s bile duct. The cancer is caused by mutations in the DNA of the bile duct cells. According to the Mayo Clinic​, it is a type of tumor that is “very difficult to treat.”

In the US 6,000 people develop cholangiocarcinoma. It is much more prevalent in Asia and the Middle East. 

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars